Skip to content

News & Events

Orphelia Pharma fund raising

28 January 2020

ORPHELIA Pharma raises 4 m€ to fund its commercial operations and clinical developments

French family offices join as new shareholders and Board members

Paris and Lyon, January 28th , 2020 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric drugs in the fields of oncology and neurology, announces it has raised 4 million € in December 2019. The proceeds will be used to grow the company’s team, develop its commercial and clinical infrastructure and advance its projects.

Initiative OCTALFA led this financing round and was joined by three French family offices managed by serial entrepreneurs, namely Ravenala holding (Alain Tornier), PAF Kapital (Christophe Pasik, Jean-François Auffret and Pierre Ferran) and Cemag (André Ulmann).

« We thank all our shareholders for their confidence in our venture and our programs », said Hugues Bienaymé, founder and CEO of ORPHELIA Pharma. « In 2020, we plan to record our first revenues with the launch of Kigabeq® and Ivozall® and initiate two clinical trials. We will also apply for a pharmaceutical establishment license in France and we anticipate to hire 7 new people. »

In addition, the company announced that André Ulmann and Christophe Pasik have joined ORPHELIA Pharma’s Board of Directors.

« We are particularly pleased to have Alain, André and Christophe with us. Their track record as successful entrepreneurs will be of invaluable help in guiding ORPHELIA Pharma to building a portfolio of paediatric medicines for rare and severe diseases » added Gilles Alberici, Chairman of ORPHELIA Pharma. « We look forward to working with them to accelerate the structuring of the company and to develop and launch new effective medicines for children. »

About ORPHELIA Pharma

ORPHELIA Pharma is a biopharmaceutical company based in Paris and Lyon that develops and markets drugs for the treatment of rare and serious paediatric diseases.

Our mission is to provide patients with essential hospital products in the fields of epilepsy and oncology with formulations adapted to the paediatric population. Our first product, Kigabeq®, obtained its Marketing Authorization in September 2018 and is being launched in Europe. Our second product, Ivozall®, was granted a European marketing authorization in November 2019 for the treatment of Acute lymphoblastic Leukaemia. ORPHELIA Pharma also conducts research projects through academic and industrial collaborations.